Skip to content

CeriBell, Inc. CBLL Return on equity

Return on equity at other companies

IAR
Integra LifeSciencesIART
-38.6%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-149.7%+4,074pp
iRadimed logo
iRadimedIRMD
25%+1.2pp
Teladoc Health logo
Teladoc HealthTDOC
-12.4%-5.4pp
Cerence Inc. logo
Cerence Inc.CRNC
-12.8%-6.0pp
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
-53.1%-17.4pp

Other financials

Income statement

See full
Revenue$26.5M+29.3%
Gross profit$23.1M+28.4%
Operating income-$20.7M-46.0%
Net income-$19.7M-54.5%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$45.3M-70.5%
Total debt$22.1M+1.6%
Total equity$140.8M-22.2%
Total assets$178.1M-16.6%

Cash flow

See full
Operating cash flow-$19.3M-69.2%
CapEx$125.0K-15.5%
Free cash flow-$19.4M-68.1%

Valuation

See full
Market cap$748.61M+15.6%
Enterprise value$725.47M+40.7%
P/S7.9×-1.2×

Profitability

See full
Gross margin87.7%+0.5pp
Operating margin-68.3%+5.5pp
Net margin-63.5%+1.0pp
FCF margin-52%-1.4pp

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio10.4×-6.9×

Where this comes from

Calculated from CeriBell, Inc.’s reported figures.

Based on trailing twelve months.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CeriBell, Inc.'s return on equity?
CeriBell, Inc. (CBLL) reported return on equity of -37.5% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.